Aksu Feyza, Aksu Burhan, Unlu Nermin, Karaca Turan, Ayvaz Suleyman, Erman Hayriye, Uzun Hafize, Keles Nursen, Bulur Sule, Unlu Ercument
a Department of Cardiology , Istanbul Medeniyet University, Goztepe Training and Research Hospital , Istanbul , Turkey ;
b Department of Pediatric Surgery , Istanbul Medeniyet University, Goztepe Training and Research Hospital , Istanbul , Turkey ;
Ren Fail. 2016 Aug;38(7):1089-98. doi: 10.1080/0886022X.2016.1194142. Epub 2016 Jun 16.
Contrast induced nephropathy (CIN) is a major cause of morbidity, and increased costs as well as an increased risk of death. This study was evaluated effects of exogenous sphingosylphosphorylcholine (SPC) administration on CIN in rats. Eight animals were included in each of the following eight groups: control, control phosphate-buffered solution (PBS), control SPC 2, control SPC 10, CIN, CIN PBS, CIN SPC 2 and CIN SPC 10. The induced nephropathy was created by injected with 4 g iodine/kg body weight. SPC was administered 3 d at a daily two different doses of 2 μm/mL and 10 μm/mL intraperitoneally. The severity of renal injury score was determined by the histological and immunohistochemical changes in the kidney. Malondialdehyde (MDA), nitric oxide (NO) and superoxide dismutase (SOD) were determined to evaluate the oxidative status in the renal tissue. Treatment with 2 and 10 μM SPC inhibited the increase in renal MDA, NO levels significantly and also attenuated the depletion of SOD in the renal injuryCIN. These data were supported by histopathological findings. The inducible nitric oxide synthase positive cells and apoptotic cells in the renal tissue were observed to be reduced with the 2 and 10 μM SPC treatment. These findings suggested that 2 and 10 μM doses can attenuate renal damage in contrast nephropathy by prevention of oxidative stress and apoptosis. The low and high dose SPC may be a promising new therapeutic agent for CIN.
对比剂肾病(CIN)是发病、成本增加以及死亡风险升高的主要原因。本研究评估了外源性鞘氨醇磷酸胆碱(SPC)给药对大鼠CIN的影响。以下八组每组纳入8只动物:对照组、对照磷酸盐缓冲液(PBS)组、对照SPC 2组、对照SPC 10组、CIN组、CIN PBS组、CIN SPC 2组和CIN SPC 10组。通过以4 g碘/千克体重注射诱导肾病。SPC以2μm/mL和10μm/mL两种不同剂量每天腹腔注射3天。通过肾脏的组织学和免疫组化变化确定肾损伤评分的严重程度。测定丙二醛(MDA)、一氧化氮(NO)和超氧化物歧化酶(SOD)以评估肾组织中的氧化状态。用2μM和10μM SPC治疗可显著抑制肾MDA、NO水平的升高,并减轻肾损伤CIN中SOD的消耗。这些数据得到了组织病理学结果的支持。观察到用2μM和10μM SPC治疗后肾组织中诱导型一氧化氮合酶阳性细胞和凋亡细胞减少。这些发现表明,2μM和10μM剂量可通过预防氧化应激和细胞凋亡减轻对比剂肾病中的肾损伤。低剂量和高剂量SPC可能是一种有前景的CIN新型治疗药物。